Last updated: February 20, 2026
What is Sulfisoxazole?
Sulfisoxazole (CAS: 298-87-3) is a sulfonamide antimicrobial agent introduced in the 1950s. It inhibits dihydropteroate synthase, blocking bacterial folic acid synthesis. Its clinical application has decreased due to resistance and the development of newer antibiotics, but it retains relevance in specific settings.
Market Overview
Sulfisoxazole’s primary use has been in urinary tract infections (UTIs) and combination therapies. It is available as capsules, suspension, and injectable forms.
Manufacturing and Suppliers
Few large-scale pharmaceutical manufacturers produce sulfisoxazole globally, primarily in India, China, and the US. Key suppliers include Sun Pharma, Mayne Pharma, and generic drug producers.
Regulatory Status
Sulfisoxazole is generally considered off-patent. However, regulatory approvals vary: it remains approved in some countries but has been withdrawn or not approved in others.
Market Size and Growth
The global antibiotics market was valued at approximately $55 billion in 2022, with sulfonamides representing a minor segment, estimated around $250 million. Sulfisoxazole has limited market growth prospects due to resistance and declining use.
Investment Considerations
Competitive Landscape
- Generics: Dominated by Indian and Chinese manufacturers.
- Pipeline: Few novel formulations or combination therapies targeting sulfisoxazole.
Patent and Regulatory Outlook
- No active patents; market exists in the generics space.
- Regulatory status is stable in some regions but uncertain where use has diminished.
R&D and Innovation
Limited R&D focus on sulfisoxazole; potential exists for combination therapies in resistant infections, but no significant current development.
Resistance and Usage Trends
Increased bacterial resistance to sulfonamides has resulted in decreased clinical use. The shift towards broad-spectrum antibiotics reduces sulfisoxazole's relevance.
Pricing and Profitability
- Low manufacturing costs.
- Margins are thin due to high competition and commoditization.
Supply Chain and Manufacturing Risks
- Quality control variability, especially in generic manufacturing.
- Dependence on raw materials sourced from limited regions.
Investment Risks
- Decreasing clinical demand due to resistance.
- Regulatory uncertainties in some markets.
- Limited R&D pipeline reduces potential for future growth.
Investment Opportunities and Outlook
- Niche uses: specific resistant infections may sustain some demand.
- Combination formulations: potential if resistance issues intensify.
- Licensing or niche market entry: limited due to low profitability and demand.
Key Data Summary
| Aspect |
Details |
| Market size |
Approx. $250 million globally (small segment of antibiotics market) |
| Growth prospects |
Declining due to resistance and shifts to newer antibiotics |
| Main producers |
Sun Pharma, Mayne Pharma, Indian generics |
| Patent status |
Off-patent |
| Regulatory status |
Approved in some countries, withdrawn or unapproved elsewhere |
| Resistance trend |
Increasing resistance, limiting clinical use |
Key Takeaways
Sulfisoxazole has diminishing relevance in the current antimicrobial landscape. Its production is commoditized, with limited innovation. Market size is small and declining, driven by resistance and shifting prescribing practices. Investment is primarily in the generic manufacturing sector with low profit margins and regulatory risks. Significant growth potential exists only through niche applications or reformulation efforts in resistant infections.
FAQs
1. Is sulfisoxazole a profitable investment?
Profitability is limited; margins are thin and declining due to resistance, low demand, and commoditization.
2. Are there new formulations or combination therapies in development?
Current development is minimal; some research explores combining sulfisoxazole with other agents for resistant infections, but no major pipeline exists.
3. What are the regulatory risks?
Approval status varies, with some regions withdrawing approval or not renewing licenses, increasing regulatory risk.
4. How does resistance impact sulfisoxazole's future?
Rising resistance among bacteria reduces clinical utility, further shrinking the market.
5. Can niche markets sustain sulfisoxazole demand?
Potential exists in specific, resistant infections, but overall demand remains limited.
References
[1] Market Data Forecast. (2022). Antibiotics Market Size & Share.
[2] U.S. FDA. (2020). Drug Approval and Labeling Status for Sulfisoxazole.
[3] WHO. (2019). Global Antibiotic Resistance Surveillance System.
[4] Indian Pharmacopoeia. (2021). Sulfonamides monograph.
[5] Statista. (2023). Global Antibiotics Market Revenue.
